Edwards Lifesciences Corporation Provides Sales Guidance for the First Quarter of 2020; Revises Sales Guidance for the Year 2020; Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2019
The company provided that 2020 sales guidance for the company is now expected to be $4.6 to $5.0 billion versus the company's previous range of $4.5 to $5.0 billion.
The company recorded a impairment of long-lived assets of $40.6 million charge in the fourth quarter ended December 31, 2019 and a $116.2 million charge in the fourth quarter of 2018 related to the other-than-temporary impairment of certain developed technology and in-process research and development acquired as part of the acquisition of Valtech Cardio Ltd.